| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $173,674,655 ) (Continued on the next page) |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG1HL069315 | BMT Core - MSK | 000 | 26 | NIH | 7/22/2026 | $264,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01HG012103 | Deciphering the Genomics of Gene Network Regulation of T Cell and Fibroblast States in Autoimmune Inflammation | 001 | 5 | NIH | 6/19/2026 | $1,119,571 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA285296 | ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and Utilization | 001 | 3 | NIH | 4/28/2026 | $696,147 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 001 | 5 | NIH | 2/17/2026 | $71,885 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 000 | 5 | NIH | 1/23/2026 | $646,946 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA300788 | Inflammatory Signaling in the Leptomeninges | 000 | 2 | NIH | 3/3/2026 | $730,398 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA292178 | Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response | 000 | 2 | NIH | 2/27/2026 | $246,840 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM156454 | Decoding the Ubiquitin and Autophagy Signaling Networks | 000 | 2 | NIH | 2/19/2026 | $440,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 001 | 5 | NIH | 6/5/2026 | $1,244,214 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 002 | 1 | NIH | 4/7/2026 | $0 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 001 | 1 | NIH | 4/7/2026 | $46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 001 | 1 | NIH | 4/7/2026 | -$46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31AI191721 | Role of Arid1a in NK cell development and antiviral immunity | 000 | 1 | NIH | 4/3/2026 | $46,564 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R34HL184529 | Microbiome manipulation through oral live biotherapeutic product (LBP) for the treatment of gut acute graft-versus-host disease (GVHD) | 000 | 1 | NIH | 7/8/2026 | $281,722 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA318433 | Access and Outcomes of Radioligand Therapy for US Veterans with Prostate Cancer | 000 | 1 | NIH | 8/6/2026 | $708,377 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI196346 | Understanding and manipulating microbiome ecology to curb gut-borne infections. | 000 | 1 | NIH | 2/20/2026 | $3,519,992 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01EB039472 | Fast motion-tolerant pediatric MRI with reduced anesthesia | 000 | 1 | NIH | 8/18/2026 | $636,110 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM161744 | Investigating histone glycation as a new dynamic epigenetic mark | 000 | 1 | NIH | 4/6/2026 | $528,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA307864 | Precision Radiotheranostics Targeting Oncogenic Mutations | 000 | 1 | NIH | 7/15/2026 | $150,551 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA308278 | Overcoming chronic inflammation-driven T cell quiescence in gastric adenocarcinoma | 000 | 1 | NIH | 4/6/2026 | $730,097 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08AI201873 | T Cell Precursor-Induced Immune Reprogramming After Hematopoietic Stem Cell Transplantation | 000 | 1 | NIH | 8/18/2026 | $194,616 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA301202 | Innate & Adaptive Determinants of Post-CAR Cytokine Release Syndrome | 000 | 1 | NIH | 3/31/2026 | $452,540 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA315216 | Improve precision medicine for renal cell carcinoma patients of African ancestry through computational and functional genomics | 000 | 1 | NIH | 8/10/2026 | $690,977 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R50CA305244 | Instituting NCI-funded thyroid and head and neck cancer studies | 000 | 2 | NIH | 8/17/2026 | $201,870 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA309345 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancer | 000 | 1 | NIH | 3/19/2026 | $715,002 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01HG014186 | Approaches for engineering transcriptional state of fibroblasts and other differentiated cell types | 000 | 2 | NIH | 8/10/2026 | $789,739 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA312519 | Characterizing germline determinants of tumor development and response to treatment | 000 | 1 | NIH | 7/1/2026 | $546,842 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA310056 | Oxygen Sensing and Ferroptosis in Cancer | 000 | 1 | NIH | 5/12/2026 | $614,260 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA311340 | Mediation Analysis of Epidemiologic Data from Multiple Incomplete Data Sources | 000 | 1 | NIH | 6/30/2026 | $366,662 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA303125 | Hematopoietic stem cell encoded anti-tumor immunity: mechanisms and function | 000 | 1 | NIH | 7/1/2026 | $745,471 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA310060 | Identifying spatial tumor microenvironment signatures for risk stratification in primary melanoma | 001 | 1 | NIH | 5/5/2026 | $2,733 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA310060 | Identifying spatial tumor microenvironment signatures for risk stratification in primary melanoma | 000 | 1 | NIH | 4/24/2026 | $690,557 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA315594 | Artificial intelligence-based integration of genomic and histopathologic data to improve precision cancer medicine | 000 | 1 | NIH | 7/16/2026 | $140,400 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA314714 | Understanding of mutant splicing factor-derived novel protein isoforms in clonal hematopoietic disorders and antigen presentation. | 000 | 1 | NIH | 7/7/2026 | $137,631 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | OT2CA320058 | REWIRE-CAN - Rewiring Cancer with Novel Signalling Therapies | 000 | 1 | NIH | 6/19/2026 | $1,710,054 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA318448 | Optimization of structure-guided models of peptide presentation and T-cell receptor specificity | 000 | 1 | NIH | 8/11/2026 | $731,937 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R33CA274717 | Mobile phone-based deep learning algorithm for oral lesion screening in low-resource settings | 002 | 4 | NIH | 7/14/2026 | $66,340 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R33CA274717 | Mobile phone-based deep learning algorithm for oral lesion screening in low-resource settings | 001 | 4 | NIH | 6/23/2026 | $226,791 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA312225 | CD4 T cells and immune cell triads in anti-tumor immunity | 000 | 1 | NIH | 6/30/2026 | $671,252 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UH3CA290241 | CD28-KITv CAR T cells with PD-1 dominant negative receptor | 000 | 3 | NIH | 5/7/2026 | $2,639,991 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS150328 | Mechanistic Insights into XPR1 Phosphate Export and Brain Calcification | 000 | 1 | NIH | 8/20/2026 | $464,565 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA300233 | The PERSON intervention: Using Patient portals to Elicit essential patient-Reported elements of communication with clinicians Supporting person-centered ONcologic care | 000 | 1 | NIH | 6/30/2026 | $745,458 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R33CA302491 | Programmable nucleic acid cytometry for unraveling heterogeneity in tumors and therapies | 000 | 2 | NIH | 8/7/2026 | $418,176 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R33CA277833 | Reducing the chasm in behavioral health care for older adults with cancer: Development of the Center for Implementation Research in Cancer in Later Life (CIRCL) | 001 | 4 | NIH | 8/10/2026 | $705,619 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35CA305347 | Overcoming Resistance to Targeted Therapy in Breast Cancer | 000 | 2 | NIH | 7/22/2026 | $1,056,000 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA250917 | Origins and functions of pancreatic cancer-associated fibroblasts | 000 | 7 | NIH | 6/18/2026 | $444,325 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35CA304457 | Understanding and Targeting Aberrant RNA Splicing in Leukemia | 000 | 2 | NIH | 7/29/2026 | $1,015,176 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99AI196248 | Investigating the developmental and transcriptional bases for distinct functions of IL-10+ and IL-10− Treg cells | 000 | 1 | NIH | 3/27/2026 | $167,951 |
| | 2026 | 2026 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21NS144867 | Characterization and Inhibition of the Interactions of the Alpha-Secretase ADAM17 with the Neuronal-Myelin Signaling Complex Upon Spinal Cord Injury | 000 | 1 | NIH | 5/5/2026 | $484,000 |
|
